生物技术通报 ›› 2026, Vol. 42 ›› Issue (7): 67-80.doi: 10.13560/j.cnki.biotech.bull.1985.2025-1022

• 综述与专论 • 上一篇    下一篇

胚乳生物反应器表达重组蛋白的研究进展

李灿妮1, 潘炜松1(), 吴泰茹2, 吴川3, 曾宝强3, 李伟展3   

  1. 1.湖南农业大学生物科学技术学院,长沙 410125
    2.湖南诺合新生物科技有限公司,长沙 410000
    3.香港教育大学科学与环境学系,中国 香港 999077
  • 收稿日期:2025-09-24 出版日期:2026-07-26 发布日期:2026-07-20
  • 通讯作者: 潘炜松joux19@163.com
  • 基金资助:
    “香港裘槎基金会”2023/2024中国内地来访学者计划

Research Progress in the Expression of Recombinant Proteins in Endosperm Bioreactors

LI Can-ni1, PAN Wei-song1(), WU Tai-ru2, WU Chuan3, Keung Eric Tsang Po3, LI Wei-zhan3   

  1. 1.College of Bioscience and Biotechnology, Hunan Agricultural University, Changsha 410125
    2.Hunan Nuohexin Biotechnology Co. , Ltd. , Changsha 410000
    3.Department of Science and Environment, The Education University of Hong Kong, Hong Kong 999077, China
  • Received:2025-09-24 Published:2026-07-26 Online:2026-07-20

摘要:

植物表达系统以其低成本、可持续性、规模化潜力、安全性与环保性等优势,成为生产重组蛋白及生物活性代谢物(如药用蛋白、疫苗、酶、抗体、维生素、类黄酮、类胡萝卜素等)的理想平台。其中,植物胚乳凭借其天然的生物合成与储存能力,被视为生产这类活性物质的优质生物反应器。本文系统评述了植物胚乳生物反应器在分子农业领域的应用,并通过与其他主流表达系统的比较,凸显了胚乳生物反应器的综合优势。本文重点综述了利用胚乳生物反应器生产药用蛋白、酶、抗体、疫苗等活性物质的最新研究进展与实际应用案例。针对胚乳表达系统中目的蛋白表达量偏低的挑战,深入探讨了通过增强转录效率进行优化的策略。同时,系统分析了利用糖基化代谢工程实现人源化修饰,以解决植物源药物免疫原性问题。最后,讨论了当前制约转基因植物源产品商业化的关键因素(如法规、公众接受度、纯化成本等),并展望了该技术未来的发展前景,特别是在利用胚乳生产高价值生物制品方面的巨大潜力。

关键词: 胚乳生物反应器, 植物生物反应器, 重组蛋白, 启动子, 糖基化修饰

Abstract:

The plant expression system has emerged as an ideal platform for producing recombinant proteins and bioactive metabolites—such as therapeutic proteins, vaccines, enzymes, antibodies, vitamins, flavonoids, and carotenoids—due to its low cost, sustainability, scalability, safety, and environmental friendliness. Among these systems, the plant endosperm is considered as a high-quality bioreactor for synthesizing and storing active substances because of its natural biosynthetic and storage capabilities. This article provides a systematic review of the applications of plant endosperm bioreactors in molecular agriculture and highlights their comprehensive advantages compared to other mainstream expression systems. It focuses on recent research advancements and practical applications involving the production of therapeutic proteins, enzymes, antibodies, and vaccines using endosperm bioreactors. To address the challenge of low expression levels of target proteins in the endosperm system, the article explores optimization strategies aimed at enhancing transcription efficiency. Furthermore, it systematically analyzes the use of glycosylation metabolic engineering to achieve humanized modifications, thereby mitigating the immunogenicity issues associated with plant-derived drugs. Finally, the article discusses key factors currently limiting the commercialization of transgenic plant-derived products, such as regulatory hurdles, public acceptance, and purification costs, and offers a forward-looking perspective on the future development of this technology, emphasizing its significant potential for producing high-value bioproducts using endosperm.

Key words: endosperm bioreactor, plant bioreactor, recombinant protein, promoter, glycosylation modification